Lilly says Foundayo cuts diabetes risk by 57% (LLY:NYSE)

Eli Lilly (NYSE: LLY) reported that its drug Foundayo reduced the 10-year risk of type 2 diabetes and cardiovascular disease in overweight/obese individuals. The company's GF Value™ suggests it is undervalued by 25.9%, with a GF Score™ of 96. Insiders sold $3.46B in shares, while 25 gurus hold positions, with 12 adding and 10 trimming.

Micron MU reported strong Q4 earnings and guidance, driven by data center revenue growth. Eli Lilly LLY announced positive results in a weight loss trial. Paramount Global PARA and Warner Bros. Discovery WBD merger was approved. Oracle ORCL shares rose on upbeat guidance. Nike NKE, McCormick MKC, and others are set to report earnings today.

Eli Lilly's oral GLP-1 drug, Foundayo (orforglipron), showed significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease in post-hoc analyses of the ATTAIN-1 trial. The 17.2 mg dose reduced diabetes risk by 57% and cardiovascular disease risk by 18% compared to placebo. These findings suggest potential long-term cost savings for patients and healthcare systems, according to the company.

Eli Lilly (LLY) reported that its drug Foundayo (orforglipron) showed significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight. Post-hoc analyses of the ATTAIN-1 trial showed a 57% reduction in diabetes risk and an 18% reduction in cardiovascular disease risk at the highest dose (17.2 mg) compared to placebo. The findings were published in Diabetes, Obesity and Metabolism.

Eli Lilly's experimental weight-loss regimen outperformed its top-selling drug in trials. Drug tariffs challenge smaller biotechs. Medicaid coverage may be lost by legal immigrants. New rule may raise costs for importing drugs. Lundbeck may acquire Xeris Biopharma.

Eli Lilly's Phase 3 ACHIEVE-4 trial showed Foundayo (orforglipron) was non-inferior to insulin glargine in reducing major cardiovascular events in type 2 diabetes patients with obesity. Foundayo also improved A1C, weight, and other cardiometabolic health measures. The trial, presented at EASD and published in The Lancet, involved 2,749 participants across multiple countries.